<?xml version="1.0" encoding="UTF-8"?>
<p>Some of these off-label regimens can potentially cause serious adverse events such as ventricular arrhythmias causing sudden cardiac arrest and sudden cardiac death. For this reason, we decided to establish national guidelines on early recognition and management of the potential arrhythmogenic risks of some pharmacological therapy used in treatment of COVID-19.</p>
